Picture of Ampio Pharmaceuticals logo

AMPE Ampio Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+19.16%
3m+722.04%
6m+86.39%
1yr-37.39%
Volume Change (%)
10d/3m-91.99%
Price vs... (%)
52w High-57.58%
50d MA-8.06%
200d MA+50.27%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-193.4%
Return on Equity-130.71%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Ampio Pharmaceuticals EPS forecast chart

Profile Summary

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the research, development, and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. The Company's lead product candidate, Ampion has immunomodulatory action and anti-inflammatory effects, which provide a treatment for individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK); osteoarthritis related to other joints, such as hip, shoulder, ankle and hand; and the widespread inflammation associated with COVID-19 infection. Ampion is in development as an intra-articular injection treatment for severe OAK, an intravenous (IV) and inhaled treatment for hospitalized severe and/or critical COVID-19 patients, and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19, referred to as Long-COVID. Its clinical studies include AP-013, AP-017, AP-019 and AP-018.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
March 24th, 2010
Public Since
May 19th, 2011
No. of Shareholders
200
No. of Employees
21
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
15,085,792

AMPE Share Price Performance

Upcoming Events for AMPE

Q4 2022 Ampio Pharmaceuticals Inc Earnings Release

Q1 2023 Ampio Pharmaceuticals Inc Earnings Release

Similar to AMPE

FAQ

Or unlock with your email

Or unlock with your email